Novo Nordisk touts weight-loss advantage of CagriSema while facing its own messaging critique

Novo Nordisk reported that its experimental obesity drug CagriSema delivered a 12.4% average weight loss after 60 weeks in a Phase 3 study of type-2 diabetes patients, outperforming the 9.1% loss recorded for Eli Lilly's tirzepatide at a 5 mg weekly dose. The company’s headline claimed “superior weight loss versus tirzepatide,” a phrasing that omits the crucial dose limitation disclosed in the trial. Novo has previously sued Lilly, alleging that the rival’s marketing overstated its drugs’ benefits by ignoring dose-specific data.

In an earlier head-to-head trial (REIMAGINE 4), CagriSema 2.4 mg/2.4 mg achieved weight loss comparable to tirzepatide 15 mg, but failed to prove superiority or non-inferiority for blood-sugar control. These mixed results highlight how clinical trial outcomes depend on the exact doses, patient groups, and endpoints studied. The author argues that Novo should apply the same caution to its own public messaging as it demands of competitors.